首页> 美国卫生研究院文献>Journal for Immunotherapy of Cancer >An open label randomized Phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-naïve stage IV or recurrent non-small cell lung cancer (NSCLC) (CheckMate 227)

【2h】

An open label randomized Phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-naïve stage IV or recurrent non-small cell lung cancer (NSCLC) (CheckMate 227)

机译：一项针对nvolumab或nivolumab联合ipilimumab与铂类双重化疗（PT-DC）的初治IV期或复发性非小细胞肺癌（NSCLC）患者的开放标签随机III期临床试验（CheckMate 227）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

期刊名称 Journal for Immunotherapy of Cancer
作者
Matthew Hellmann; Suresh Ramalingam; Martin Reck; Ken OByrne; Luis Paz-Ares; Christopher T Harbison; Prabhu Bhagavatheeswaran; Faith Nathan; Julie Brahmer;
展开▼
作者单位

展开▼
年(卷),期 2015(3),Suppl 2
年度 2015
页码 P154
总页数 2
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. An open label randomized Phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-na?ve stage IV or recurrent non-small cell lung cancer (NSCLC) (CheckMate 227) [J] . Matthew Hellmann, Suresh Ramalingam, Martin Reck, Journal for ImmunoTherapy of Cancer . 2015,第S2期

机译：一项针对nivolumab初治IV期或复发性非小细胞肺癌（NSCLC）患者的nivolumab或nivolumab联合ipilimumab与铂类双重化疗（PT-DC）的开放标签随机III期试验（CheckMate 227）
2. Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial [J] . Reck Martin, Schenker Michael, Lee Ki Hyeong, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2019,第期

机译：Nivolumab Plus inpilemimab与化疗作为高级非小细胞肺癌的一线治疗，具有高肿瘤突变负担：患者报告的结果由随机，开放标签，III期检查培育227试验结果
3. CheckMate-227 shows superior progression-free Survival for Nivolumab in combination with Ipilimumab versus Chemotherapy in the First-line Treatment of non-small cell Lung Cancer Patients with high Tumor Mutational Burden [J] . Oncology research and treatment. . 2018,第4期

机译：checkmate-227显示了Nivolumab的优异进展生存期与Ipilimalab与化疗组合，在肿瘤突变负担的非小细胞肺癌患者的一线治疗中
4. The clinical efficacy of transfusion of cytokine-induced killer cells combined with chemotherapy and XiaoJi decoction in patients with stage IIIB/IV non-small cell lung cancer [C] . Liuning Li, Jiaying Liu, Xiaoshu Chai, IEEE International Conference on Bioinformatics and Biomedicine . 2014

机译：细胞因子诱导的杀伤细胞输注结合化学疗法和消积汤治疗IIIB / IV期非小细胞肺癌的临床疗效
5. Assessing the effectiveness of palliative chemotherapy for non-small cell lung cancer: A phase IV study of patients treated at Ontario's cancer centres [D] . Harrison, Lyndsay Dawn. 2012

机译：评估姑息化疗对非小细胞肺癌的有效性：在安大略省癌症中心接受治疗的患者的IV期研究
6. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized Open-Label Phase III Trials (CheckMate 017 and CheckMate 057) [O] . Leora Horn, David R. Spigel, Everett E. Vokes, -1

机译：在接受过治疗的晚期非小细胞肺癌患者中Nivolumab与多西他赛的比较：两项随机开放标签III期试验（CheckMate 017和CheckMate 057）的两年结果
7. An open label randomized Phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-naïve stage IV or recurrent non-small cell lung cancer (NSCLC) (CheckMate 227) [O] . Matthew Hellmann, Suresh Ramalingam, Martin Reck, 2015

机译：一项针对nvolumab或nivolumab联合ipilimumab与铂类双重化疗（PT-DC）的初治IV期或复发性非小细胞肺癌（NSCLC）患者的开放标签随机III期临床试验（CheckMate 227）

An open label randomized Phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-naïve stage IV or recurrent non-small cell lung cancer (NSCLC) (CheckMate 227)

著录项

相似文献

相关主题

期刊订阅